Excimer laser atherectomy combined with drug‑coated balloon angioplasty for the treatment of chronic obstructive femoropopliteal arterial disease

Liu,Hui; Gu,Yan; Yang,Sen; He,Ju; Zhang,Fuxian

doi:10.3892/etm.2019.8362

Excimer laser atherectomy combined with drug‑coated balloon angioplasty for the treatment of chronic obstructive femoropopliteal arterial disease

Authors:
- Hui Liu
- Yan Gu
- Sen Yang
- Ju He
- Fuxian Zhang
View Affiliations

Affiliations: Department of Vascular Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China, Department of Vascular Surgery, Tianjin First Central Hospital, Tianjin 300192, P.R. China
Published online on: December 20, 2019 https://doi.org/10.3892/etm.2019.8362
Pages: 1887-1895
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present retrospective study was to evaluate the feasibility, safety and the primary results following application of excimer laser atherectomy (ELA) combined with adjunctive drug‑coated balloon angioplasty (DCBA) as the first‑line endovascular treatment for patients with chronic obstructive femoropopliteal arterial disease. The baseline characteristics and angiographic variables of all patients who underwent ELA for stable chronic obstructive femoropopliteal arterial disease at Tianjin First Central Hospital (Tianjin, China) between May and December 2017 were collected. Information on clinical characteristics, including the 12‑month primary patency rate, technical success rate, procedural success rate, bailout stenting rate, target lesion revascularization and major adverse events, was obtained following review of the patients' medical records. A descriptive analysis was performed on all variables. Kaplan‑Meier curves were plotted for the primary patency rate. The present study included 17 consecutive patients (age, 68.9±7.4 years; 94.1% males) who were followed up for 12 months after the intervention. Adjunctive BA was performed in 100% of the cases. The occlusion length was 23.3±8.9 cm (range, 5.6‑40.5 cm). The technical success rate was 100% and the procedural success rate was 88.2%. Bailout stenting was required in 5 of the 17 patients (29.4%) and the 12‑month primary patency rate was 82.4%. The clinically driven target lesion revascularization rate was 5.9% at 12 months. An embolic protection device was used in 23.5% of the patients. The following adverse events were reported: Distal embolization requiring treatment, 5.9% (1 patient with embolic protection device); and flow‑limiting dissection requiring treatment, 5.9%. In the present study, there were no major adverse events (all‑cause death, unplanned major amputation or target lesion revascularization) at 30 days after the intervention. Therefore, ELA combined with adjunctive DCBA for the treatment of chronic obstructive femoropopliteal arterial disease appears to be safe, practicable and associated with a high procedural success rate; furthermore, endoluminal‑driven atherectomy may effectively reduce the requirement for stent placement in the lower limb arteries and is associated with long‑term patency.

View Figures

View References

1	Ferreira M, Lanziotti L, Monteiro M, Abuhadba G, Capotorto LF, Nolte L and Fearnot N: Superficial femoral artery recanalization with self-expanding nitinol stents: Long-term follow-up results. Eur J Vasc Endovasc Surg. 34:702–708. 2007. View Article : Google Scholar : PubMed/NCBI
2	Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, et al: Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The femoral artery stenting trial (FAST). Circulation. 116:285–292. 2007. View Article : Google Scholar : PubMed/NCBI
3	Zeller T, Tiefenbacher C, Steinkamp HJ, Langhoff R, Wittenberg G, Schlüter M, Buergelin K, Rastan A, Krumsdorf U, Sixt S, et al: Nitinol stent implantation in TASC A and B superficial femoral artery lesions: The femoral artery conformexx trial (FACT). J Endovasc Ther. 15:390–398. 2008. View Article : Google Scholar : PubMed/NCBI
4	Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, Loewe C, Cejna M, Lammer J and Minar E: Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 115:2745–2749. 2007. View Article : Google Scholar : PubMed/NCBI
5	Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA and Ansel G; VIVA Physicians, Inc, : Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 69:910–919. 2007. View Article : Google Scholar : PubMed/NCBI
6	Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group, ; Bell K, Caporusso J, Durand-Zaleski I, et al: Inter-society consensus for the management of peripheral arterial disease (TASCII). Eur J Vasc Endovasc Surg. 33 (Suppl 1):S1–S75. 2007. View Article : Google Scholar : PubMed/NCBI
7	Gur I, Lee W, Akopian G, Rowe VL, Weaver FA and Katz SG: Clinical outcomes and implications of failed infrainguinal endovascular stents. J Vasc Surg. 53:658–666. 2011. View Article : Google Scholar : PubMed/NCBI
8	Armstrong EJ, Saeed H, Alvandi B, Singh S, Singh GD, Yeo KK, Anderson D, Westin GG, Dawson DL, Pevec WC and Laird JR: Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther. 21:34–43. 2014. View Article : Google Scholar : PubMed/NCBI
9	Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J and Minar E: Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 354:1879–1888. 2006. View Article : Google Scholar : PubMed/NCBI
10	Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, et al: Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 3:267–276. 2010. View Article : Google Scholar : PubMed/NCBI
11	Scheinert D, Laird JR Jr, Schröder M, Steinkamp H, Balzer JO and Biamino G: Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. J Endovasc Ther. 8:156–166. 2001. View Article : Google Scholar : PubMed/NCBI
12	Laird JR, Zeller T, Gray BH, Scheinert D, Vranic M, Reiser C and Biamino G; LACI Investigators, : Limb salvage following laser-assisted angioplasty for critical limb ischemia: Results of the LACI multicenter trial. J Endovasc Ther. 13:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
13	Bosiers M, Peeters P, Elst FV, Vermassen F, Maleux G, Fourneau I and Massin H: Excimer laser assisted angioplasty for critical limb ischemia: Results of the LACI Belgium study. Eur J Vasc Endovasc Surg. 29:613–619. 2005. View Article : Google Scholar : PubMed/NCBI
14	Serino F, Cao Y, Renzi C, Mascellari L, Toscanella F, Raskovic D, Tempesta P, Bandiera G and Santini A: Excimer laser ablation in the treatment of total chronic obstructions in critical limb ischaemia in diabetic patients. Sustained efficacy of plaque recanalisation in mid-term results. Eur J Vasc Endovase Surg. 39:234–238. 2010. View Article : Google Scholar
15	Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U and Ricke J: Inhibition of restenosis in femoropopliteal arteries: Paclitaxel-coated versus uncoated balloon: Femoral paclitaxel randomized pilot trial. Circulation. 118:1358–1365. 2008. View Article : Google Scholar : PubMed/NCBI
16	Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B and Speck U: Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 358:689–699. 2008. View Article : Google Scholar : PubMed/NCBI
17	Ansel GM and Lumsden AB: Evolving modalities for femoropopliteal interventions. J Endovasc Ther. 16 (Suppl 2):II82–II97. 2009. View Article : Google Scholar : PubMed/NCBI
18	Grotti S, Liistro F, Angioli P, Ducci K, Falsini G, Porto I, Ricci L, Ventoruzzo G, Turini F, Bellandi G and Bolognese L: Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: Three-year results of the DEBATE-ISR study. J Endovasc Ther. 23:52–57. 2016. View Article : Google Scholar : PubMed/NCBI
19	Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, Tesorio T, Cota L, Popusoi G, Pucciarelli A, et al: Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 7:411–415. 2014. View Article : Google Scholar : PubMed/NCBI
20	Kokkinidis DG, Hossain P, Jawaid O, Alvandi B, Foley TR, Singh GD, Waldo SW, Laird JR and Armstrong EJ: Laser atherectomy combined with drug-coated balloon angioplasty is associated with improved 1-year outcomes for treatment of femoropopliteal in-stent restenosis. J Endovasc Ther. 25:81–88. 2018. View Article : Google Scholar : PubMed/NCBI
21	Van den Berg JC, Pedrotti M, Canevascini R, Chimchila Chevili S, Giovannacci L and Rosso R: In-stent restenosis: Mid-term results of debulking using excimer laser and drug-eluting balloons: Sustained benefit? J Invasive Cardiol. 26:333–337. 2014.PubMed/NCBI
22	Sixt S, Carpio Cancino OG, Treszl A, Beschorner U, Macharzina R, Rastan A, Krankenberg H, Neumann FJ and Zeller T: Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 58:682–686. 2013. View Article : Google Scholar : PubMed/NCBI
23	Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S and Jones DN: Recommended standards for reports dealing with lower extremity ischemia: Revised version. J Vasc Surg. 26:517–538. 1997. View Article : Google Scholar : PubMed/NCBI
24	Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzari DE and Leon MB: A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. Am J Cardiol. 103:923–929. 2009. View Article : Google Scholar : PubMed/NCBI
25	Ranke C, Creutzig A and Alexander K: Duplex scanning of the peripheral arteries: Correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 18:433–440. 1992. View Article : Google Scholar : PubMed/NCBI
26	Shammas NW, Shammas GA, Helou TJ, Voelliger CM, Mrad L and Jerin M: Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: A retrospective review from a single center. Cardiovasc Revasc Med. 13:224–227. 2012. View Article : Google Scholar : PubMed/NCBI
27	Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, et al: Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: Initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 8:92–101. 2015. View Article : Google Scholar : PubMed/NCBI
28	Gonzalez L, Chen A, Lin PH, Pisimisis G, Barshes NR, Bechara CF and Kougias P: Latest recanalization techniques for complex superficial femoral artery occlusions. J Cardiovasc Surg (Torino). 53:487–494. 2012.PubMed/NCBI
29	Golomb BA, Dang TT and Criqui MH: Peripheral arterial disease: Morbidity and mortality implications. Circulation. 114:688–699. 2006. View Article : Google Scholar : PubMed/NCBI
30	He Y, Jiang Y, Wang J, Fan L, Li X and Hu FB: Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J Vasc Surg. 44:333–338. 2006. View Article : Google Scholar : PubMed/NCBI
31	Luo Y, Li X, Li J, Wang X, Qiao Y, Hu D, Merriam PA and Ma Y: Combined effects of smoking and peripheral arterial disease on all-cause and cardiovascular disease mortality in a Chinese male cohort. J Vasc Surg. 51:673–678. 2010. View Article : Google Scholar : PubMed/NCBI
32	Dormandy JA and Rutherford RB: Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic inter-society consensus (TASC). J Vasc Surg. 31:S1–S296. 2000.PubMed/NCBI
33	Bosiers M, Torsello G, Gissler HM, Ruef J, Müller-Hülsbeck S, Jahnke T, Peeters P, Daenens K, Lammer J, Schroë H, et al: Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 16:261–269. 2009. View Article : Google Scholar : PubMed/NCBI
34	Zhou W, Bush RL, Lin PH, Peden EK and Lumsden AB: Laser atherectomy for lower extremity revascularization: An adjunctive endovascular treatment option. Vasc Endovascular Surg. 40:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
35	Sultan S, Tawfick W and Hynes N: Cool excimer laser-assisted angioplasty (CELA) and tibial balloon angioplasty (TBA) in management of infragenicular arterial occlusion in critical lower limb ischemia (CLI). Vasc Endovascular Surg. 47:179–191. 2013. View Article : Google Scholar : PubMed/NCBI
36	Dave RM, Patlola R, Kollmeyer K, Bunch F, Weinstock BS, Dippel E, Jaff MR, Popma J and Weissman N; CELLO Investigators, : Excimer laser recanalization of femoropopliteal lesions and 1-year patency: Results of the CELLO registry. J Endovasc Ther. 16:665–675. 2009. View Article : Google Scholar : PubMed/NCBI
37	Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G and Bolognese L: Drug-eluting balloon in peripheral intervention for the superficial femoral artery: The DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 6:1295–1302. 2013. View Article : Google Scholar : PubMed/NCBI
38	Rosenfield K, Jafr MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, et al: Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 373:145–153. 2015. View Article : Google Scholar : PubMed/NCBI
39	Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, et al: Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 131:495–502. 2015. View Article : Google Scholar : PubMed/NCBI
40	McKinsey JF, Goldstein L, Khan HU, Graham A, Rezeyat C, Morrissey NJ, Sambol E and Kent KC: Novel treatment of patients with lower extremity ischemia: Use of percutaneous atherectomy in 579 lesions. Ann Surg. 248:519–528. 2008.PubMed/NCBI
41	Wissgott C, Kamusella P, Lüdtke C and Andresen R: Excimer laser atherectomy after unsuccessful angioplasty of TASC C and D lesions in femoropopliteal arteries. J Cardiovasc Surg (Torino). 54:359–365. 2013.PubMed/NCBI
42	Lüdtke CW, Scheer F, Kamusella P, Wissgott C and Andresen R: Transpopliteal balloon-assisted excimer-laser atherectomy for the treatment of chronic femoropopliteal occlusions: Feasibility and initial results. Clin Med Insights Cardiol. 8 (Suppl 2):S23–S28. 2014.
43	Sangiorgi G, Lauria G, Airoldi F, Godino C, Politi L, Colombo A, Clerici G, Modena MG and Biondi-Zoccai G: Retrograde popliteal access as bail-out strategy for challenging occlusions of the superficial femoral artery: A multicenter registry. Catheter Cardiovasc Interv. 79:1188–1193. 2012. View Article : Google Scholar : PubMed/NCBI